FOR CMOs, CSOs AND VPs OF CLINICAL DEVELOPMENT
Your trial did not fall behind
during execution.
It fell behind before
the protocol was finalized.
In a 30-minute conversation, I identify where your program is most likely to break down before it does. No commercial pressure. No commitment. Just an honest assessment.
EU · USA · UK · Canada
China · Japan · Australia
25+ years in clinical operations
Phase I through IV
Free Strategic
Diagnosis Session
30 minutes · No commitment · Real value
By clicking the "Send Now" button, you agree to our Legal Disclaimer and Privacy Notice.
I - IV
clinical phases, from early development to post-market
If this resonates with you
The problems that keep repeating because the root cause has not yet been addressed.
01
The trial is behind schedule and internal reviews have not converged on a cause.
02
The CRO submits regular reports, but the actual risk still does not appear in any of them.
03
Data quality issues identified too late to address without additional cost.
04
The budget was built on assumptions that did not survive contact with execution.
05
You have changed CROs before. The same patterns followed.
06
Go/No-Go decisions that should be scientific end up being delayed by internal dynamics.
None of these are execution problems. They are management problems, with an origin that almost always precedes what is visible on the surface.
What happens in 30 minutes
A conversation worth placing in your calendar.
1
We map your current program
Phase, geography, team structure and critical milestones. We work from what exists, not from a generic template.
2
I identify the three highest-risk points
Operational, regulatory or governance. I name what is most exposed and explain the reasoning behind it.
3
You leave with a concrete direction
Not a presentation deck. A specific read of where your program stands and what to prioritize first.
This is not a sales meeting. If there is room for deeper work together, I will say so clearly. If there is not, you still finish the conversation with something useful.
Flavia Christina Ladwig Robles
Founder · Vortex Pharma Solution
Over 25 years managing global clinical trials across the EU, USA, UK, Canada, Ireland, China, Japan, Australia, New Zealand and South Africa, from Phase I through post-market phase. Every failure I observed carried the same signature: a management decision made too early or too late, with insufficient information. Vortex Pharma Solution was built to address that, not with more tools or more meetings, but with real clinical governance from day one.
25+ years
10+ markets
Phase I to IV
Risk-based mgmt
Regulatory
Frequently asked questions
Before you decide.
Is the session genuinely free?
Yes. Thirty minutes, no charge and no obligation. We do this because the diagnosis itself delivers value, and it is the most honest way to assess whether a longer engagement makes sense for both sides.
Our study is on track. Why would we need this now?
The trials with the highest cost of failure often appeared healthy three months before they did not. In clinical development, prevention consistently offers the best cost-to-benefit ratio.
.
We already work with a CRO. Would this still be relevant?
In most cases, yes. The most recurring problems are not inside the CRO but in the governance structure surrounding it. A CRO delivers what it is contracted and directed to deliver.
Do you work with smaller biotechs or only large pharma?
Both. Scale changes the size of the problem, rarely the nature of it. The root cause almost always involves management decisions made without the right framework in place.
30 minutes of conversation.
A clear picture of where your program stands.
I work with a limited number of sessions per month to give each one the preparation it deserves. If you are managing an active study or planning your next one, this is the right moment to talk.
© 2026 Vortex Pharma Solution · Privacy Policy